Press Releases

Long-Term Follow-Up Data from LEAP-002 Offers Insights into Hepatocellular Carcinoma Treatment Pipeline Data in Endometrial Carcinoma Among Studies to be Presented NUTLEY, N.J., May 20, 2025...

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis...

Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for...

Eisai today announced a label update for LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in the United States to include clinical efficacy data for...

Eisai today announced results from a post-hoc analysis from the Phase 3 REFLECT trial, which looked at efficacy outcomes characterized by depth of response in patients with unresectable...